Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
Source : https://www.sciencedirect.com/science/article/pii/S221304892200070X?via=ihub
Resistance mutations can be detected in 75% of CLL patients progressing under BTK inhibitor therapy. Using semiquantitative wild-type-blocking (WTB) R...
Conclusions: "Wild-type blocking PCR is a sensitive, cost-effective and routinely applicable method for the detection of BTK resistant CLL clones but misses low frequency mutations when using ctDNA."
Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36428480/
Chimeric antigen receptor T (CAR-T) cells are genetically modified autologous T cells that have revolutionized the treatment of relapsing and refractory haematological malignancies. In this review we present molecular pathways...
Conclusions: In this review we present molecular pathways involved in the activation of CAR-T cells, describe in details the structures of receptors and the biological activity of CAR-T cells currently approved for clinical practice in the European Union, and explain the functional differences between them. Finally, we present the potential for...
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36453136/
Chimeric antigen receptor T-cell (CAR T) therapy has shown promising efficacy in relapsed and refractory diffuse large B cell lymphoma (DLBCL). While most patients undergo CAR T infusion with active...
Conclusions: This data supports proceeding with treatment in CAR T candidates regardless of their response to immediate pre-CAR T therapy. Interim therapeutic interventions should be considered in patients who have known risk factors for poor outcomes (bulky disease, high LDH).
A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany - Oncology and Therapy
Source : https://link.springer.com/article/10.1007/s40487-021-00169-x
Introduction The measurement of minimal residual disease (MRD) with clonoSEQ® can be used in the assessment of B-cell lymphoid tumor burden throughout treatment with accuracy, sensitivity and standardization when compared...
Conclusions: Based on the underlying model, clonoSEQ® can support German health insurance funds to use high-cost drugs more efficiently in the treatment of myeloma.
Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis
Source : https://www.pathologyjournal.rcpa.edu.au/article/S0031-3025(22)00265-3/fulltext
Diffuse large B-cell lymphoma (DLBCL) is the most common form of B-cell non-Hodgkin lymphoma (B-NHL) with significant morbidity and mortality despite advancements in treatment. Lymphoma and autoimmune disease both result...
Relevance: This project aimed to explore the relationship between red cell autoimmunity and DLBCL. DAT positivity was more common in DLBCL as compared to healthy controls (20.4% vs 3.7%, p=0.0005). Univariate analysis found a non-significant trend towards poorer overall survival in the DAT positive (DAT ) compared to the DAT negative (DAT–)...